Mednet Logo
HomePediatric Hematology/OncologyQuestion

How do you incorporate blinatumomab into therapy for a pediatric or AYA patient with isolated CNS relapse of B-ALL, if at all?

1 Answers
Mednet Member
Mednet Member
Pediatric Hematology/Oncology · The University of Texas MD Anderson Cancer Center

I try to prioritize CAR-T in this setting. Getting there depends on logistics such as financial clearance/collection though. If late relapse or if there is a delay in getting CAR-T, would treat with AALL1331 Arm D (with XRT in mtn), substituting block 3 of blina for block 3 on Arm C (to get more CNS...

Register or Sign In to see full answer

How do you incorporate blinatumomab into therapy for a pediatric or AYA patient with isolated CNS relapse of B-ALL, if at all? | Mednet